Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

Major depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing to treatment-resistant depression (TRD).

IntroductionMajor depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing ...

Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, has emerged as an effective therapeutic agent for the management of treatment-resistant depression. Repeated treatments with ...

Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026.

The company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, ...

(A ketamine-derived drug called esketamine is approved for some people as part of treatment-resistant major depressive disorder in a certified clinical setting.) But doctors have developed a ...

The condition is believed to affect around one-third of adults with major depressive disorder, so there is a considerable need for new, effective treatments for TRD. Esketamine, a molecular ...

After the rejection of Lykos Therapeutics’ MDMA-based PTSD treatment tempered excitement for psychedelic therapeutics, a ...